37 recruiting, 37 unknown, 17 not yet recruiting, 9 completed. 64 Phase 2, 24 Phase 1, 10 Phase 3, 6 Early Phase 1, 6 Not applicable.
Follow PD-1 inhibitor: new trials by email Literature Review of PD-1 inhibitor trials Research Report on PD-1 inhibitor
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer H101, Camrelizumab - Pancreatic Cancer | Phase 2 | Not yet recruiting | Fudan University | 30 | 2026-12-01 | 2025-08-07 |
| MRD and Imaging Guided Adaptive Neoadjuvant Therapy for Resectable NSCLC PD-1 inhibitor, Carboplatin, Nab-paclitaxel - Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Peking University People's Hospital | 100 | 2026-11-01 | 2026-10-21 |
| A Multicenter, Randomized, Controlled Phase III Clinical Trial on Adjuvant Intensified Therapy for Patients With Residual Disease After Neoadjuvant Treatment for Triple-negative Breast Cancer Capecitabine and PD-1 inhibitor, PD-1 inhibitor, Capecitabine - Newly Diagnosed Triple-negative Breast Cancer | Phase 3 | Not yet recruiting | Shandong Cancer Hospital and Institute | 852 | 2026-10-17 | 2026-10-09 |
| Chemotherapy Combined With or Without Short-Course Radiotherapy Versus Chemotherapy Alone as Neoadjuvant Therapy for High-Risk Locally Advanced Colon Cancer With pMMR/MSS short-course radiotherapy, Serplulimab, CapOx(Capecitabine+ Oxaliplatin) - Locally Advanced Colon Cancer, pMMR | Phase 3 | Not yet recruiting | Fudan University | 480 | 2026-10-15 | 2026-10-16 |
| A Prospective Trial Evaluating the Efficacy and Tumor Immune Microenvironment Remodeling Induced by SFI Plus PD-1 Inhibitors and PBC in Resectable NSCLC Shenqi Fuzheng Injection - Tear Disorder, Resectable Locally Advanced Non-Squamous NSCLC | Phase 4 | Not yet recruiting | Anhui Provincial Cancer Hospital | 30 | 2026-10-15 | 2026-09-28 |
| A Phase II Study of Anlotinib + PD-1 Inhibitor vs. PD-1 Inhibitor Maintenance After First-Line Chemoimmunotherapy in Advanced ESCC (Esophageal Squamous Cell Carcinoma) anlotinib + PD-1 inhibitor, PD-1 inhibitor - Esophageal Cancer (EC) | Phase 2 | Recruiting | Sun Yat-sen University | 112 | 2026-10-12 | 2026-10-07 |
| Local Ablation Plus Systemic Therapy for Metachronous Liver and/or Lung Oligometastases From Nasopharyngeal Carcinoma CT-guided percutaneous local ablation, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Neoplasm Metastasis | Phase 2 | Not yet recruiting | Sun Yat-sen University | 138 | 2026-10-01 | 2026-09-17 |
| ctDNA-Guided Immunotherapy for dMMR/MSI-H Colon Cancer PD-1 inhibitor, CTLA-4 inhibitor, ctDNA/MRD testing - Colon Cancer, Deficient Mismatch Repair | Phase 2 | Recruiting | Fudan University | 23 | 2026-09-14 | 2026-09-25 |
| Serine/Glycine-Restricted Diet With Chemoradiotherapy for Rectal Cancer Serine/Glycine-Restricted Diet, CAPOX Chemotherapy, PD-1 Inhibitor - Locally Advanced Rectal Cancer (LARC) | Phase 1 / Phase 2 | Not yet recruiting | Xuelei Ma MD | 140 | 2026-08-31 | 2026-09-09 |
| Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Immunochemotherapy for Resectable Esophageal Cancer: A Target Trial Emulation Study Radiotherapy, Platinum-based Chemotherapy, PD-1 Inhibitor - Esophageal Squamous Cell Carcinoma (ESCC) | Not yet recruiting | Henan Cancer Hospital | 400 | 2026-08-20 | 2026-08-21 | |
| Sintilimab Plus Gossypol Acetate in Advanced Colorectal Cancer Sintilimab, Gossypol Acetate - Advanced Colorectal Cancer | Phase 2 | Not yet recruiting | Peking University People's Hospital | 32 | 2026-07-15 | 2026-06-25 |
| RAIRI Model-Guided Adjuvant Therapy in Nasopharyngeal Carcinoma PD-1 inhibitor, Capecitabine - Nasopharyngeal Carcinoma (NPC) | Phase 3 | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 651 | 2026-05-01 | 2026-06-04 |
| SCRT Based iTNT vs. LCRT Based TNT for MSS Locally Advanced Rectal Cancer short-course radiaotherapy, long-course chemoradiaothearpy, Capecitabine - Locally Advanced Rectal Cancer (LARC), MSS (Microsatellite Stable) | Phase 3 | Not yet recruiting | Fudan University | 612 | 2026-05-01 | 2026-04-24 |
| Safety and Preliminary Efficacy of [177Lu]Lu-RTX-2358 Combined With Immune Checkpoint Inhibitors in Patients With FAP-positive Metastatic Non-Small Cell Lung Cancer [177Lu]Lu-RTX-2358 - Metastatic Non-small Cell Lung Cancer | Early Phase 1 | Recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 36 | 2026-04-28 | 2026-07-14 |
| Using Healthy Gut Bacteria to Boost Immune Treatment for Advanced Bowel Cancer yFMT - Colorectal Cancer Metastatic, Fecal Microbiota Transplantation | Early Phase 1 | Not yet recruiting | The First Affiliated Hospital of Xiamen University | 10 | 2026-03-31 | 2026-03-20 |
| A Study of Liposomal Irinotecan Plus 5-FU/LV HAIC With Lenvatinib and a PD-1 Inhibitor in Advanced ICC Hepatic Arterial Infusion Chemotherapy (HAIC) with Liposomal Irinotecan, 5-Fluorouracil, Leucovorin, Lenvatinib, PD-1 Inhibitor - Intrahepatic Cholangiocarcinoma | Phase 2 | Not yet recruiting | Tianjin Medical University Cancer Institute and Hospital | 30 | 2026-03-09 | 2026-02-25 |
| Real-World RAIRI-Guided Risk Stratification for Adjuvant Therapy Benefit After Chemoradiotherapy in NPC PD-1 inhibitor, Capecitabine - Nasopharyngeal Carcinoma (NPC) | Recruiting | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 900 | 2026-01-01 | 2026-06-03 | |
| Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, PD-1 inhibitor, TS-1 - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 84 | 2025-11-18 | 2026-01-06 |
| AT1019 Plus SBRT and PD-1 Inhibitor for Advanced Solid Tumors: An IIT Study AT1019 - Advanced Solid Tumors | Phase 1 | Recruiting | The Affiliated Hospital of Xuzhou Medical University | 12 | 2025-11-12 | 2025-12-16 |
| Phase I/II Clinical Study of GT201 Injection as Monotherapy or in Combination With PD-1 Inhibitor for Advanced Solid Tumors GT201, IL-2, PD-1 inhibitor - Advanced Solid Tumors | Phase 1 / Phase 2 | Recruiting | Grit Biotechnology | 78 | 2025-11-01 | 2026-08-19 |
Showing 20 of 112. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (13) · Carcinoma, Hepatocellular (8) · Esophageal Neoplasms (7) · Neoplasms (6) · Nasopharyngeal Carcinoma (5) · Head and Neck Neoplasms (4) · Stomach Neoplasms (4) · Colonic Neoplasms (3) · Colorectal Neoplasms (3) · Esophageal Squamous Cell Carcinoma (3) · Melanoma (3) · Neoplasm Metastasis (3) · Pancreatic Neoplasms (3) · Triple Negative Breast Neoplasms (3) · Bites and Stings (2)
Sun Yat-sen University (14) · Fudan University (8) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (6) · Tianjin Medical University Cancer Institute and Hospital (6) · Hunan Cancer Hospital (4) · Ruijin Hospital (4) · Sichuan University (4) · The First Affiliated Hospital of Nanchang University (4) · BioAtla, Inc. (3) · Second Affiliated Hospital, Zhejiang University, School of Medicine (3) · Amgen (2) · Fujian Cancer Hospital (2) · Janssen Research & Development, LLC (2) · Peking Union Medical College Hospital (2) · Peking University People's Hospital (2)
China (86) · United States (16) · Spain (7) · Taiwan (6) · France (4) · Australia (3) · Hong Kong (3) · Japan (3) · Belgium (2) · Canada (2) · Greece (2) · Italy (2) · Netherlands (2) · Poland (2) · South Korea (2)
Wen-Yang Liu, MD (2) · Xiubao Ren, MD. PhD. (2) · You Lu, MD (2) · Zhen Zhang, MD (2) · Aiping Zhou, M.D. (1) · Baiyong Shen, M.D&Ph.D (1) · Baiyong Shen, M.D.&Ph.D (1) · Biao Zhu, PhD (1) · Binghao Li, Medical PhD (1) · Dehui Zou, Dr. (1) · Depei Wu, M.D. (1) · Dongsheng Zhang, PhD (1) · Feng Duan (1) · Gang Huang (1)
PMID 17762336, PMID 20354531, PMID 20956625, PMID 20969765, PMID 23578724, PMID 24035327, PMID 26541606, PMID 28453692, PMID 29097493, PMID 31534737, PMID 32067509, PMID 32989552, PMID 35399603, PMID 35703113, PMID 35748749, PMID 35995696, PMID 37143538, PMID 37921708, PMID 38024475, PMID 38160327, PMID 38261958, PMID 38572751, PMID 38579194, PMID 39038917, PMID 39462179, PMID 39545610, PMID 39909032, PMID 39990653, PMID 40251674, PMID 40812353, PMID 40882625, PMID 41300985, PMID 41654611, PMID 41784638, PMID 42320551, PMID 42332718, PMID 4830803, PMID 8874455
P01CA234212 (1)